Ask AI
ProCE Banner Activity

Hemophilia: Integrating Hemostatic Rebalancing Therapies Into Personalized Care

Slideset

View these downloadable slides to learn about the pathophysiology of hemophilia as well as 3 rebalancing agents that help patients with moderate to severe disease. Rebalancing inhibitors' mechanism of action is described, adverse events incurred during clinical trials are included, as well as comparisons between the requirements of managing the agents. 

Released: March 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme

Target Audience

This educational activity is intended for hematologists and other healthcare professionals who care for patients with hemophilia. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Demonstrate the ability to justify the use of hemostatic rebalancing therapies by explaining their mechanisms of action, clinical indications, and patient selection criteria in the context of moderate to severe hemophilia

  • Interpret current clinical trial data on rebalancing therapies and apply this evidence to guide treatment selection for patients with and without inhibitors

  • Assess individual patient characteristics to identify candidates for rebalancing therapies and develop personalized prophylaxis management strategies that optimize clinical outcomes

  • Evaluate the risks and benefits of integrating rebalancing agents into clinical care, including thrombotic risk mitigation, monitoring strategies, and shared decision-making approaches